- Home
- REGN
REGN
Regeneron Pharmaceuticals Inc.
as 03-27-2025 4:00pm EST
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | N/A | IPO Year: | 1991 |
| Target Price: | $990.84 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | 38.34 | EPS Growth: | 10.27 |
| 52 Week Low/High: | $629.02 - $1211.20 | Next Earning Date: | 05-01-2025 |
| Revenue: | $14,202,000,000 | Revenue Growth: | 8.27% |
| Revenue Growth (this year): | 4.75% | Revenue Growth (next year): | 5.70% |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Is Regeneron Pharmaceuticals, Inc. (REGN) a Promising Biotech Stock According to Wall Street Analysts
GlobeNewswire
2 days ago
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
Zacks
2 days ago
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
Insider Monkey
2 days ago
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst?
StockStory
7 days ago
3 Reasons to Sell REGN and 1 Stock to Buy Instead
StockStory
8 days ago
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
Insider Monkey
10 days ago
Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires
Insider Monkey
10 days ago
Jim Cramer Wants You to ‘Own’ Regeneron Pharmaceuticals (REGN) Shares
Compare REGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.